A Pragmatic Eight-Week Phase IV Study of Bamlanivimab/LY-CoV555 for Emergency Passive Immunity Against COVID-19.
Bamlanivimab is designed to block the COVID -19 virus from attaching to, entering, and infecting human cells. Health Canada has authorized the emergency use of this medication for COVID-19 but we need more information about its safety and efficacy before it can be widely used.
COVID-19 can be difficult to treat. Studies are underway to determine if medications, including bamlanivimab, can reduce hospital stays and serious illness in people with COVID-19.
Participants will receive either standard of care or bamlanivimab, given as a one-time intravenous infusion in a COVID-19 clinic. Participants must test positive for COVID-19, be over 18 years of age, and meet other medical criteria for being high-risk for moderate or severe COVID-19.
UPDATE June 17, 2021: The study is now closed to enrollment. Study activities are ongoing, but no additional participants will be recruited. A huge thank you to the participants who are generously providing their time and information in this study. Be kind, be calm, be safe!
Study activities are currently ongoing, but additional participants are no longer required.